The α-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice

Hepatology Research

Volumn 39, Issue 5, 2009, Pages 490-500

  Okada, Kosuke ^a   Yanagawa, Toru ^a   Warabi, Eiji ^a   Yamastu, Keiko ^a   Uwayama, Junya ^a   Takeda, Koichi ^b   Utsunomiya, Hirotoshi ^b   Yoshida, Hiroshi ^a   Shoda, Junichi ^a   Ishii, Tetsuro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

A170; Acarbose; Obesity; p62; Sequestosome 1; Steatosis

Indexed keywords

ABC TRANSPORTER A1; ACARBOSE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA GLUCOSIDASE INHIBITOR; ASPARTATE AMINOTRANSFERASE; CELL PROTEIN; CHOLESTEROL; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SEQUESTOSOME 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY FAT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FAT CONTENT; FATTY LIVER; FOOD INTAKE; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; UPREGULATION; WEIGHT GAIN;

EID: 65449133190     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00478.x     Document Type: Article

References (21)

1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Hepatology 1999; 116: 1413-19.
2. Jansen PL. Non-alcoholic steatohepatitis. Eur J Med 2004; 16: 1079-85.
3. Day CP, James OFW. Steatohepatits: A tale of two "hits"? Gastroenterology 1998; 114: 842-5.
4. Green RM. NASH-Hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003; 38: 14-17.
5. Sheth SG, Gordon FD, Chopar S. Nonalcoholic steatohepatitis. Ann Intern Med 1999; 107: 450-5.
6. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998-1003.
7. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
8. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
9. Chiasson J-L, Josse RG, Hanefeld M, Karasik A, Laaksok K. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-7.
10. Chiasson J-L, Josse RG, Leiter LA et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1191-4.
11. Lieber CS, Leo MA, Mak KM et al. Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun 2004; 315: 699-703.
12. Rodriguez A, Durán A, Selloum M et al. Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab 2006; 3: 211-22.
13. Moscat J, Diaz-Meco MT, Wooten MW. Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci 2007; 32: 95-100.
14. Ishii T, Yanagawa T, Kawane T et al. Murine peritoneal macrophages induce a novel 60-kDa protein with structural similarity to a tyrosine kinase p56lck-associated protein in response to oxidative stress. Biochem Biophys Res Commun 1996; 226: 456-60.
15. Komatsu M, Waguri S, Koike M et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007; 131: 1149-63.
16. Nagasawa T, Inada Y, Nakano S et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006; 536: 182-91.
17. Puls AS, Schmidt F, Grawe F, Stabel S. Interaction of protein kinase C zeta with ZIP, a novel protein kinase C-binding protein. Proc Natl Acad Sci USA 1997; 94: 6191-6.
18. Joung I, Strominger JL, Shin J. Molecular cloning of a phosphotyrosine-independent ligand of the p56lck SH2 domain. Proc Natl Acad Sci USA 1996; 93: 5991-5.
19. Ishii T, Itoh K, Takahashi S et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000; 275: 16023-9.
20. Yang S, Zhu H, Li Y et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378: 259-68.
21. Bakker SJ, Ijzerman RG, Teerlink T, Westerhoff HV, Gans RO, Heine RJ. Cytosolic triglycerides and oxidative stress in central obesity: The missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? Atherosclerosis 2000; 148: 17-21.